PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Kumar, Shiv ^a   Kim, Jaebong ^a  

^a Hallym University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1H PYRAZOLO(4,3 H)QUINAZOLINE 3 CARBOXAMIDE 4,5 DIHYDRO 1 (2 HYDROXYETHYL) 8 [[5 (4 METHYL 1 PIPERAZINYL) 2 (TRIFLUOROMETHOXY)PHENYL]AMINO]; 2 CYANO N (2,5 DIBROMOPHENYL) 3 HYDROXYCROTONAMIDE; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ANTINEOPLASTIC AGENT; ARISTOLOLACTAM; CYCLAPOLIN1; DAP 81; GSK 461364A; HMN 176; PHA 680626; PHOSPHOPEPTIDE; POLO LIKE KINASE 1 INHIBITOR; POLO LIKE KINASE INHIBITOR; POLOXIN; POLOXIPAN; PURPUROGALLIN; RIGOSERTIB; SBE 13; SCYTONEMIN; UNCLASSIFIED DRUG; VOLASERTIB; WORTMANNIN; [4 [(9 VYCLOPENTYL 7,7 DIFLUORO 5 METHYL 6 OXO 6,7,8,9 TETRAHYDRO 5H PYRIMIDO (4,5 B)(1,4)DIAZEPIN 2 YL)AMINO] 2 FLUORO 5 METHOXY N (1 METHYLPIPERIDIN 4 YL)BENZAMIDE]; CELL CYCLE PROTEIN; MOLECULAR LIBRARY; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE;

CARCINOGENESIS; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DOMAIN; PROTEIN TARGETING; REVIEW; ANTAGONISTS AND INHIBITORS; CELL CYCLE; DRUG EFFECTS; MITOSIS; MOLECULAR LIBRARY; THERAPEUTIC USE;

CARCINOGENESIS; CELL CYCLE; CELL CYCLE PROTEINS; HUMANS; MITOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 84947224577     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/705745     Document Type: Review

References (86)

1. E. P. Balskus, R. J. Case, and C. T. Walsh, "The biosynthesis of cyanobacterial sunscreen scytonemin in intertidal microbial mat communities, " FEMS Microbiology Ecology, vol. 77, no. 2, pp. 322-332, 2011.
2. J. G. Dillon and R. W. Castenholz, "The synthesis of the UVscreening pigment, scytonemin, and photosynthetic performance in isolates from closely related natural populations of cyanobacteria (Calothrix sp.), " EnvironmentalMicrobiology, vol. 5, no. 6, pp. 484-491, 2003.
3. P. J. Proteau, W. H. Gerwick, F. Garcia-Pichel, and R. Castenholz, "The structure of scytonemin, an ultraviolet sunscreen pigment fromthe sheaths of cyanobacteria, " Experientia, vol. 49, no. 9, pp. 825-829, 1993.
4. D. Inoue andN. Sagata, "The Polo-like kinase Plx1 interactswith and inhibitsMyt1 after fertilization of Xenopus eggs, "TheEMBO Journal, vol. 24, no. 5, pp. 1057-1067, 2005.
5. A. K. Roshak, E. A. Capper, C. Imburgia, J. Fornwald, G. Scott, andL. A.Marshall, "Thehumanpolo-likekinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase, " Cellular Signalling, vol. 12, no. 6, pp. 405-411, 2000.
6. A. Kumagai and W. G. Dunphy, "Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts, " Science, vol. 273, no. 5280, pp. 1377-1380, 1996.
7. C. McInnes, M. Mezna, and P. M. Fischer, "Progress in the discovery of Polo-like kinase inhibitors, " Current Topics in Medicinal Chemistry, vol. 5, no. 2, pp. 181-197, 2005.
8. C. S. Stevenson, E. A. Capper, A. K. Roshak et al., "The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore, " Journal of Pharmacology and Experimental Therapeutics, vol. 303, no. 2, pp. 858-866, 2002.
9. X. S. Liu, H. Li, B. Song, and X. Liu, "Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery, " EMBO Reports, vol. 11, no. 8, pp. 626-632, 2010.
10. X. Yang, H. Li, Z. Zhou et al., "Plk1-mediated phosphorylation of topors regulates p53 stability, " The Journal of Biological Chemistry, vol. 284, no. 28, pp. 18588-18592, 2009.
11. K. Strebhardt, "Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy, " Nature Reviews Drug Discovery, vol. 9, no. 8, pp. 643-660, 2010.
12. G. Zhang, Z. Zhang, and Z. Liu, "Scytonemin inhibits cell proliferation and arrests cell cycle through downregulating Plk1 activity in multiple myeloma cells, " Tumor Biology, vol. 34, no. 4, pp. 2241-2247, 2013.
13. R. A. Elling, R. V. Fucini, and M. J. Romanowski, "Structures of the wild-Type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands, "Acta Crystallographica Section D: Biological Crystallography, vol. 64, no. 9, pp. 909-918, 2008.
14. K. Gumireddy, M. V. Reddy, S. C. Cosenza et al., "ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent, " Cancer Cell, vol. 7, pp. 275-286, 2005.
15. M. Kothe, D. Kohls, S. Low et al., "Structure of the catalytic domain of human polo-like kinase 1, " Biochemistry, vol. 46, no. 20, pp. 5960-5971, 2007.
16. P. Lnrt, M. Petronczki, M. Steegmaier et al., "The smallmolecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1, " Current Biology, vol. 17, no. 4, pp. 304-315, 2007.
17. Y. Liu, K. R. Shreder, W. Gai, S. Corral, D. K. Ferris, and J. S. Rosenblum, "Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase, " Chemistry and Biology, vol. 12, no. 1, pp. 99-107, 2005.
18. E. F. Johnson, K. D. Stewart, K. W. Woods, V. L. Giranda, and Y. Luo, "Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity, " Biochemistry, vol. 46, no. 33, pp. 9551-9563, 2007.
19. J. Yuan, A. Hrlin, B. Hock, H. J. Stutte, H. Rbsamen-Waigmann, and K. Strebhardt, "Polo-like kinase, a novelmarker for cellular proliferation, " The American Journal of Pathology, vol. 150, no. 4, pp. 1165-1172, 1997.
20. I. Beria, D. Ballinari, J. A. Bertrand et al., "Identification of 4, 5-dihydro-1H-pyrazolo[4, 3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors, " Journal of Medicinal Chemistry, vol. 53, no. 9, pp. 3532-3551, 2010.
21. L. L. Garland, C. Taylor, D. L. Pilkington, J. L. Cohen, and D. D. von Hoff, "A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivativewith polo-like kinase-1-interacting properties, in patients with advanced solid tumors, " Clinical Cancer Research, vol. 12, no. 17, pp. 5182-5189, 2006.
22. H. Tanaka, N. Ohshima, M. Ikenoya, K. Komori, F. Katoh, and H. Hidaka, "HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y, " Cancer Research, vol. 63, no. 20, pp. 6942-6947, 2003.
23. I. Beria, R. T. Bossi, M. G. Brasca et al., "NMS-P937, a 4, 5-dihydro-1H-pyrazolo[4, 3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor, " Bioorganic & Medicinal Chemistry Letters, vol. 21, no. 10, pp. 2969-2974, 2011.
24. K.A.Emmitte, G.M.Adjabeng, C.W. Andrews et al., "Designof potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding, " Bioorganic & Medicinal Chemistry Letters, vol. 19, pp. 1694-1697, 2009.
25. K. A. Emmitte, C. W. Andrews, J. G. Badiang et al., "Discovery of thiophene inhibitors of polo-like kinase, " Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 3, pp. 1018-1021, 2009.
26. A. G. Gilmartin, M. R. Bleam, M. C. Richter et al., "Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis, " Cancer Research, vol. 69, no. 17, pp. 6969-6977, 2009.
27. R. N. Murugan, J.-E. Park, E.-H. Kim et al., "Plk1-Targeted smallmolecule inhibitors: molecular basis for their potency and specificity, "Molecules and Cells, vol. 32, no. 3, pp. 209-220, 2011.
28. D. Olmos, D. Barker, R. Sharma et al., "Phase I study of GSK461364, a specific and competitive polo-like kinase 1 inhibitor, in patients with advanced solidmalignancies, " Clinical Cancer Research, vol. 17, no. 10, pp. 3420-3430, 2011.
29. B. Valsasina, I. Beria, C. Alli et al., "NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologicmalignancies, " Molecular Cancer Therapeutics, vol. 11, no. 4, pp. 1006-1016, 2012.
30. L. McKenzie, S. King, L. Marcar et al., "p53-dependent repression of polo-like kinase-1 (PLK1), " Cell Cycle, vol. 9, no. 20, pp. 4200-4212, 2010.
31. M. Steegmaier, M. Hoffmann, A. Baum et al., "BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo, " Current Biology, vol. 17, no. 4, pp. 316-322, 2007.
32. K. Mross, A. Frost, S. Steinbild et al., "Phase I dose escalation and pharmacokinetic study of BI 2536, a novel polo-like kinase 1 inhibitor, in patients with advanced solid tumors, " Journal of Clinical Oncology, vol. 26, no. 34, pp. 5511-5517, 2008.
33. P. Ciceri, S. Mller, A. O'Mahony et al., "Dual kinase-bromodomain inhibitors for rationally designed polypharmacology, " Nature Chemical Biology, vol. 10, no. 4, pp. 305-312, 2014.
34. D.Rudolph, M. Steegmaier, M.Hoffmann et al., "BI 6727, a pololike kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity, " Clinical Cancer Research, vol. 15, no. 9, pp. 3094-3102, 2009.
35. P. Schffski, "Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology, " Oncologist, vol. 14, no. 6, pp. 559-570, 2009.
36. T. Lu, C. A. Laughton, S. Wang, and T. D. Bradshaw, "In Vitro Antitumor Mechanism of (E)-N-(2-methoxy-5-(((2, 4, 6-Trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide, " Molecular Pharmacology, vol. 87, no. 1, pp. 18-30, 2014.
37. M. V. R. Reddy, P. Venkatapuram, M. R. Mallireddigari et al., "Discovery of a clinical stagemulti-kinase inhibitor sodium(E)-2-{2-methoxy-5-[(2, 4, 6-Trimethoxystyrylsulfonyl)methyl] phenylamino}acetate (ON 01910.Na): synthesis, structureactivity relationship, and biological activity, " Journal of Medicinal Chemistry, vol. 54, no. 18, pp. 6254-6276, 2011.
38. A. Jimeno, J. Li, W. A. Messersmith et al., "Phase I study of ON 01910.Na, a novelmodulator of the polo-like kinase 1 pathway, in adult patients with solid tumors, " Journal of Clinical Oncology, vol. 26, no. 34, pp. 5504-5510, 2008.
39. P. Schffski, J.-Y. Blay, J. de Greve et al., "Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network of Core Institutes (NOCI), " European Journal of Cancer, vol. 46, no. 12, pp. 2206-2215, 2010.
40. C.-C. Lin, W.-C. Su, C.-J. Yen et al., "A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies, " British Journal of Cancer, vol. 110, no. 10, pp. 2434-2440, 2014.
41. M. Kang, G. Yang, R. F. Place et al., "Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth, " Cancer Research, vol. 72, no. 19, pp. 5069-5079, 2012.
42. C.McInnes, A.Mazumdar, M.Mezna et al., "Inhibitors of Pololike kinase reveal roles in spindle-pole maintenance, " Nature Chemical Biology, vol. 2, no. 11, pp. 608-617, 2006.
43. U. Peters, J. Cherian, J. H. Kim, B.H. Kwok, and T.M. Kapoor, "Probing cell-division phenotype space and Polo-like kinase function using small molecules, " Nature Chemical Biology, vol. 2, no. 11, pp. 618-626, 2006.
44. A. Santamaria, R. Neef, U. Eberspcher et al., "Use of the novel Plk1 inhibitor ZK-Thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis, "Molecular Biology of the Cell, vol. 18, no. 10, pp. 4024-4036, 2007.
45. S. Keppner, E. Proschak, G. Schneider, and B. Spnkuch, "Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1, " ChemMedChem, vol. 4, no. 11, pp. 1806-1809, 2009.
46. Y. Sato, Y.Onozaki, T. Sugimoto et al., "Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors, " Bioorganic & Medicinal Chemistry Letters, vol. 19, no. 16, pp. 4673-4678, 2009.
47. F. M. Uckun, I. Dibirdik, S. Qazi et al., "Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK), " Bioorganic and Medicinal Chemistry, vol. 15, no. 2, pp. 800-814, 2007.
48. F. Uckun, I. Dibirdik, A. Sarkissian, and S. Qazi, "In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors, " Arzneimittel-Forschung, vol. 61, no. 4, pp. 252-259, 2011.
49. S. Chen, D. Bartkovitz, J. Cai et al., "Identification of novel, potent and selective inhibitors of Polo-like kinase 1, " Bioorganic & Medicinal Chemistry Letters, vol. 22, no. 2, pp. 1247-1250, 2012.
50. N. N. Wang, Z. H. Li, H. Zhao, and et al, "Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells, " International Journal of Molecular Sciences, vol. 16, no. 1, pp. 1266-1292, 2015.
51. E. J. Hanan, R. V. Fucini, M. J. Romanowski et al., "Design and synthesis of 2-Amino-isoxazolopyridines as Polo-like kinase inhibitors, " Bioorganic & Medicinal Chemistry Letters, vol. 18, no. 19, pp. 5186-5189, 2008.
52. R. V. Fucini, E. J. Hanan, M. J. Romanowski et al., "Design and synthesis of 2-Amino-pyrazolopyridines as Polo-like kinase 1 inhibitors, " Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 20, pp. 5648-5652, 2008.
53. Y.Hikichi, K.Honda, K.Hikami et al., "TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broadspectrum preclinical antitumor activity in multiple dosing regimens, "Molecular CancerTherapeutics, vol. 11, no. 3, pp. 700-709, 2012.
54. M. E. Burkard, A. Santamaria, and P. V. Jallepalli, "Enabling and disabling polo-like kinase 1 inhibition through chemical genetics, " ACS Chemical Biology, vol. 7, no. 6, pp. 978-981, 2012.
55. K. S.Lee, T.Z. Grenfell, F. R. Yarm, andR. L. Erikson, "Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk, " Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 16, pp. 9301-9306, 1998.
56. J.-E. Park, N.-K. Soung, Y. Johmura et al., "Polo-box domain: a versatile mediator of polo-like kinase function, " Cellular and Molecular Life Sciences, vol. 67, no. 12, pp. 1957-1970, 2010.
57. W. Reindl, J. Yuan, A. Krmer, K. Strebhardt, and T. Berg, "Inhibition of polo-like kinase 1 by blocking polo-box domaindependent protein-protein interactions, " Chemistry and Biology, vol. 15, no. 5, pp. 459-466, 2008.
58. J.Yuan, M. Sanhaji, A. Krmer et al., "Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo, " The American Journal of Pathology, vol. 179, no. 4, pp. 2091-2099, 2011.
59. L. Zhang, Y.-H. Cao, S. Lu, S.-L. Sun, H.-C. Liu, and T. Lu, "Targeting the substrate binding domain of polo-like kinase 1: advances in the study of PBD1 inhibitors, " Yao Xue Xue Bao, vol. 48, no. 3, pp. 315-324, 2013.
60. A. E. H. Elia, P. Rellos, L. F.Haire et al., "Themolecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain, " Cell, vol. 115, no. 1, pp. 83-95, 2003.
61. A. E.H. Elia, L. C. Cantley, andM. B. Yaffe, "Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates, " Science, vol. 299, no. 5610, pp. 1228-1231, 2003.
62. D. M. Lowery, D. Lim, andM. B. Yaffe, "Structure and function of Polo-like kinases, " Oncogene, vol. 24, no. 2, pp. 248-259, 2005.
63. S.-M. Kim, S. Yoon, N. Choi et al., "In vivo tumor imaging using polo-box domain of polo-like kinase 1 targeted peptide, " Biomaterials, vol. 33, no. 29, pp. 6915-6925, 2012.
64. M. Kothe, D. Kohls, S. Low et al., "Selectivity-determining residues in Plk1, " Chemical Biology & Drug Design, vol. 70, no. 6, pp. 540-546, 2007.
65. P. Schffski, A. Awada, H. Dumez et al., "A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours, " European Journal of Cancer, vol. 48, no. 2, pp. 179-186, 2012.
66. C. Didier, C. Cavelier, M. Quaranta, C. Demur, and B. Ducommun, "Evaluation of Polo-like kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia, " European Journal of Pharmacology, vol. 591, no. 1-3, pp. 102-105, 2008.
67. A. Jimeno, A. Chan, G. Cusatis et al., "Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay, " Oncogene, vol. 28, no. 4, pp. 610-618, 2009.
68. S. Mahajan, S. Ghosh, E. A. Sudbeck et al., "Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [-cyano-hydroxy-methyl-N-(2, 5-dibromophenyl)propenamide], " The Journal of Biological Chemistry, vol. 274, no. 14, pp. 9587-9599, 1999.
69. M. Kowalsk and T. Pharmaceuticals, "A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients, " Febuary 2015, https://clinicaltrials.gov/ct2/show/NCT01262235.
70. Z. Yin, Y. Song, and P. H. Rehse, "Thymoquinone blocks pSer/pThr recognition by plk1 polo-box domain as a phosohate mimic, " ACS Chemical Biology, vol. 8, no. 2, pp. 303-308, 2013.
71. N. Watanabe, T. Sekine, M. Takagi et al., "Deficiency in chromosome congression by the inhibition of Plk1 polo box domaindependent recognition, "The Journal of Biological Chemistry, vol. 284, no. 4, pp. 2344-2353, 2009.
72. W. Reindl, J. Yuan, A. Krmer, K. Strebhardt, and T. Berg, "A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis, " ChemBioChem, vol. 10, no. 7, pp. 1145-1148, 2009.
73. L. Li, X.Wang, J. Chen et al., "The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of pololike kinase 1 potently inhibits cancer cell proliferation, " Acta Pharmacologica Sinica, vol. 30, no. 10, pp. 1443-1453, 2009.
74. K.-Y. Cheng, E. D. Lowe, J. Sinclair, E. A. Nigg, and L. N. Johnson, "The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex, "TheEMBO Journal, vol. 22, no. 21, pp. 5757-5768, 2003.
75. B. Garci-?Alvarez, G. de Crcer, S. Ibanez, E. Bragado-Nilsson, and G. Montoya, "Molecular and structural basis of polo-like kinase 1 substrate recognition: implications in centrosomal localization, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 9, pp. 3107-3112, 2007.
76. S. M. Yun, T. Moulaei, D. Lim et al., "Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1, " Nature Structural and Molecular Biology, vol. 16, no. 8, pp. 876-882, 2009.
77. T.Hyoda, T. Tsujioka, T.Nakahara et al., "Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest, " Cancer Science, vol. 106, no. 3, pp. 287-293, 2015.
78. S. Nuthalapati, Q. Zhou, P. Guo et al., "Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon) and ON013105, for brain tumor chemotherapy, " Pharmaceutical Research, vol. 29, no. 9, pp. 2499-2511, 2012.
79. C. Liao, J. E. Park, J. K. Bang, M. C. Nicklaus, and K. S. Lee, "Exploring potential binding modes of small drug-like molecules to the polo-box domain of human polo-like kinase 1, " ACS Medicinal Chemistry Letters, vol. 1, pp. 110-114, 2010.
80. Y. H. Kang, J.-E. Park, L.-R. Yu et al., "Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation, " Molecular Cell, vol. 24, no. 3, pp. 409-422, 2006.
81. Y. Degenhardt and T. Lampkin, "Targeting polo-like kinase in cancer therapy, " Clinical Cancer Research, vol. 16, no. 2, pp. 384-389, 2010.
82. C. McInnes and M. D. Wyatt, "PLK1 as an oncology target: current status and future potential, " Drug Discovery Today, vol. 16, no. 13-14, pp. 619-625, 2011.
83. X. Liu, M. Lei, and R. L. Erikson, "Normal cells, but not cancer cells, survive severe Plk1 depletion, " Molecular and Cellular Biology, vol. 26, no. 6, pp. 2093-2108, 2006.
84. R. Elez, A. Piiper, B. Kronenberger et al., "Tumor regression by combination antisense therapy against Plk1 and Bcl-2, " Oncogene, vol. 22, no. 1, pp. 69-80, 2003.
85. A. Esquela-Kerscher and F. J. Slack, "Oncomirs-microRNAs with a role in cancer, " Nature Reviews Cancer, vol. 6, no. 4, pp. 259-269, 2006.
86. X. Liu and R. L. Erikson, "Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 5789-5794, 2003.